Skip to main content
. Author manuscript; available in PMC: 2017 Dec 5.
Published in final edited form as: Nat Biomed Eng. 2017 Jun 5;1:0078. doi: 10.1038/s41551-017-0078

Figure 4. GLP1-ELPopt depots persist in the subcutaneous space and enhance the drug’s pharmacokinetics.

Figure 4

SPECT-CT images illustrate how long each injected construct remains in the SC space (a) and were used to calculate local depot retention at the site of SC injection (n=4) (b). Circulating GLP1-ELPopt calculated as cumulative AUC versus time can be fit with either linear or logarithmic regression (c). Corresponding plasma concentrations after the depot has been absorbed into circulation (n=3) (d) show improved pharmacokinetics with GLP1-ELPopt. The dashed line represents an approximated minimum effective concentration of GLP1-ELP, calculated with accounting for the reduced activity of the fusions (see SI Section 1.3). Data represent the mean and SEM.